Vivos Therapeutics Reports Executive Resignation; Engages CFO Portal

What Happened

• Vivos Therapeutics, Inc. announced on an 8-K that it entered into a Separation, Resignation and Executive Transition Agreement with Bradford Amman dated July 31, 2026. The filing also reports a Master Services Agreement (MSA) dated July 31, 2026 between Vivos and The CFO Portal, LLC.
• Both agreements are incorporated into the Form 8-K and are included as exhibits to the filing (Exhibit 10.1 and Exhibit 10.2).

Key Details

• Separation, Resignation and Executive Transition Agreement dated July 31, 2026 (party: Bradford Amman) — filed as Exhibit 10.1.
• Master Services Agreement dated July 31, 2026 with The CFO Portal, LLC — filed as Exhibit 10.2 (includes exhibits to the MSA).
• The 8-K covers the entry into these material agreements and the executive departure disclosure under Item 5.02; it does not summarize financial terms in the body of the report (see exhibits for full terms).

Why It Matters

• Executive departures and transition agreements can affect company leadership, continuity and near-term management responsibilities; investors should review the Separation Agreement to understand any transition timing, advisory roles or payments.
• The MSA with The CFO Portal suggests Vivos has arranged external finance or CFO-related services during the transition; review the MSA exhibit to see scope, duration and cost implications.
• For actionable detail, shareholders and analysts should read Exhibits 10.1 and 10.2 in the 8-K to assess any financial obligations or operational changes disclosed in those agreements.